Comments on: Comparative Effectiveness Stimulus Stimulates Reactions

By: Biotech Trends in 2011: Comparative Effectiveness and Personalized Medicine « The Cross-Border Biotech Blog

Tue, 04 Jan 2011 19:27:35 +0000

[...] often have to do with determining which patient is being treated – was soon bolstered by the Comparative Effectiveness provisions in the U.S. stimulus bill and new data via the FDA. The proposition has since become common knowledge, culminating in [...]

By: Biotech Trends Update: Costs Savings from Personalized Medicine Sought by PBMs, Employers, Pharma Face Legal and Privacy Hurdles « The Cross-Border Biotech Blog

Thu, 04 Feb 2010 18:22:55 +0000

[...] to act. That’s particularly unfortunate, because government is the closest thing we have to a neutral funding source for comparative effectiveness and personalized medicine research (despite also being a [...]

By: Trends in 2009: Comparative Effectiveness Meets Personalized Medicine in the Senate « The Cross-Border Biotech Blog

Thu, 02 Apr 2009 16:33:20 +0000

[...] effectiveness advocates in the Obama administration are perfectly on board with point (2), a point I made again when the U.S. Stimulus allocated $1.1 billion to comparative effectiveness rese…. It’s point (1) that most likely caused the amendment to be (predictably) rejected, [...]